GlassScriptPhysician profile
Saraswathi Saiprasad
NPI 1588977102
$2,296.88
in general payments reported to CMS, 2019-2025
32 companies · $477 in 2025
The $477 reported for 2025 was less than what a typical Endocrinology, Diabetes & Metabolism provider received nationally (typical 2025 total: $506).
See the full distribution for Endocrinology, Diabetes & Metabolism
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $534 · 2020: $261 · 2021: $80.99 · 2022: $13.51 · 2023: $313 · 2024: $618 · 2025: $477.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,408.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,408.21 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amgen INC. | $321.10 | 2019-2025 | Evenity, Enbrel, Otezla |
| Dexcom, INC. | $211.02 | 2019-2024 | Dexcom G7 Gss (161), Dexcom G6 Transmitter |
| Insulet Corporation | $208.81 | 2019-2025 | Omnipod |
| Sanofi-Aventis U.S. LLC | $157.61 | 2019-2025 | |
| Novartis Pharmaceuticals Corporation | $141.64 | 2019-2020 | |
| Medtronic, INC. | $117.64 | 2023-2025 | Minimed 780g |
| Lilly USA, LLC | $101.39 | 2019-2023 | Mounjaro, Taltz |
| Abbott Laboratories | $100.07 | 2021-2024 | Freestyle Libre |
| Merck Sharp & Dohme LLC | $72.97 | 2019-2024 | Dificid, Zinplava |
| Takeda Pharmaceuticals U.S.A., INC. | $65.98 | 2023-2025 | Entyvio, Eohilia, Gattex |
| Janssen Biotech, INC. | $56.49 | 2024 | Tremfya, Stelara |
| Laborie Medical Technologies Corp. | $54.88 | 2024 | Renovarp |
| Boehringer Ingelheim Pharmaceuticals, INC. | $54.33 | 2019-2021 | |
| Xeris Pharmaceuticals, INC. | $53.68 | 2025 | Recorlev |
| Astrazeneca Pharmaceuticals LP | $52.07 | 2019-2020 |
Show all 32 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Aurinia Pharma U.S., INC. | $48.38 | 2024 | Lupkynis |
| Radius Health, INC. | $45.13 | 2019-2020 | |
| Ucb, INC. | $42.20 | 2024 | Cimzia, Bimzelx |
| Genzyme Corporation | $41.07 | 2019-2025 | |
| Beta Bionics, INC. | $40.43 | 2024-2025 | Ilet Bionic Pancreas, Ilet Insulin Infusion Kit Contact Detach, Ilet Insulin Infusion Kit Inset |
| Aimmune Therapeutics, INC. | $40.01 | 2024-2025 | Zenpep |
| Shire North American Group INC | $35.67 | 2019 | |
| Novo Nordisk INC | $34.08 | 2019 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $33.09 | 2024 | Xifaxan |
| Ethicon US, LLC | $28.21 | 2024 | Vistaseal |
| Rgh Enterprises LLC | $27.59 | 2025 | |
| Tandem Diabetes Care, INC. | $21.34 | 2025 | T:Slim X2 Insulin Pump With Control-Iq |
| Enterra Medical, INC. | $19.21 | 2024 | |
| Braintree Laboratories, INC. | $18.81 | 2023 | Suflave |
| Corcept Therapeutics | $18.67 | 2019 | |
| Sequel Med Tech, LLC | $18.09 | 2025 | Twiist |
| Sandoz INC. | $15.22 | 2023 | Hyrimoz |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Saraswathi Saiprasad listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.